NuVasive Inc. (NASDAQ:NUVA) reached a new 52-week high on Friday . The company traded as high as $61.29 and last traded at $61.04, with a volume of 323,976 shares traded. The stock had previously closed at $59.71.

A number of equities research analysts recently weighed in on the company. Morgan Stanley restated a “hold” rating and issued a $57.00 price target on shares of NuVasive in a report on Tuesday, June 7th. Cowen and Company restated a “buy” rating and issued a $63.00 price target (up previously from $52.00) on shares of NuVasive in a report on Wednesday, April 27th. Leerink Swann restated a “buy” rating on shares of NuVasive in a report on Wednesday, April 27th. Barclays PLC upgraded NuVasive from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $58.00 to $63.00 in a report on Friday, May 27th. Finally, Brean Capital restated a “buy” rating and issued a $60.00 price target (up previously from $58.00) on shares of NuVasive in a report on Tuesday, June 7th. Four investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. NuVasive presently has a consensus rating of “Buy” and a consensus price target of $60.83.

The firm has a 50-day moving average of $57.54 and a 200 day moving average of $50.42. The stock has a market cap of $3.03 billion and a price-to-earnings ratio of 123.37.

NuVasive (NASDAQ:NUVA) last announced its earnings results on Tuesday, April 26th. The medical device company reported $0.31 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.04. The firm had revenue of $215.10 million for the quarter, compared to the consensus estimate of $205.54 million. During the same period in the previous year, the firm earned $0.30 EPS. NuVasive’s revenue for the quarter was up 11.8% on a year-over-year basis. On average, equities research analysts predict that NuVasive Inc. will post $1.51 earnings per share for the current fiscal year.

In related news, EVP Jason Hannon sold 14,534 shares of the business’s stock in a transaction that occurred on Thursday, June 16th. The stock was sold at an average price of $57.57, for a total transaction of $836,722.38. Following the sale, the executive vice president now owns 37,616 shares of the company’s stock, valued at $2,165,553.12. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Other large investors have recently made changes to their positions in the company. Redwood Investments LLC boosted its stake in shares of NuVasive by 94.6% in the fourth quarter. Redwood Investments LLC now owns 26,431 shares of the medical device company’s stock valued at $1,430,000 after buying an additional 12,851 shares during the last quarter. Russell Frank Co boosted its stake in shares of NuVasive by 300.6% in the fourth quarter. Russell Frank Co now owns 27,586 shares of the medical device company’s stock valued at $1,512,000 after buying an additional 20,700 shares during the last quarter. Mutual of America Capital Management LLC boosted its stake in shares of NuVasive by 74.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 37,313 shares of the medical device company’s stock valued at $2,019,000 after buying an additional 15,927 shares during the last quarter. First Trust Advisors LP boosted its stake in shares of NuVasive by 71.0% in the fourth quarter. First Trust Advisors LP now owns 48,197 shares of the medical device company’s stock valued at $2,608,000 after buying an additional 20,019 shares during the last quarter. Finally, Comerica Bank boosted its stake in shares of NuVasive by 0.6% in the fourth quarter. Comerica Bank now owns 54,277 shares of the medical device company’s stock valued at $2,851,000 after buying an additional 331 shares during the last quarter.

Nuvasive, Inc is a medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The Company offers two product lines: spine surgery products and biologics. The Company’s spine surgery products line offerings include thoracolumbar product offerings, cervical product offerings, Intra-Operative Monitoring (IOM) services and disposables, which are used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.